Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver crawled time : 14:00 save search
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
INKT | $0.898 3.02% 2.93% 40K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer preclinical
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published: 2024-03-06 (Crawled : 14:00) - biospace.com/
INKT | $0.898 3.02% 2.93% 40K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer tumor preclinical
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
NUWE | $0.255 -2.07% -2.12% 230K
|
Manufacturing
|
| O: 6.25%
H: 0.78%
C: -12.75%
aquadex liver disease series potential therapy
BioAdaptives Announces the Development of VeganHepPlusTM Liver Supplement Formula
Published: 2023-11-16 (Crawled : 14:00) - globenewswire.com
BDPT | $0.0006 -42.86% 21M
|
|
| O: -10.0%
H: 11.11%
C: 0.0%
liver
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
HEPA | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 2.05%
H: 29.77%
C: 1.34%
liver conference review pharmaceuticals trial phase 2
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -1.26%
meeting liver therapeutics
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
Published: 2023-11-06 (Crawled : 14:00) - biospace.com/
NDRA | $0.2334 1.11% 68K
|
Health Technology
|
| O: 3.13%
H: 4.03%
C: -5.05%
meeting liver disease
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Published: 2023-09-05 (Crawled : 14:00) - biospace.com/
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: -1.08%
H: 2.24%
C: -3.54%
MIRM | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: 0.42%
H: 7.76%
C: 4.46%
rare liver treatment acquisition pharmaceuticals therapeutics
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients with Liver Metastases – Marketscreener.com
Published: 2023-04-21 (Crawled : 14:00) - spacfeed.com
GRCY | $11.2 -3.13% 11K
|
Finance
|
| O: 0.81%
H: 2.24%
C: 0.45%
sd-101 melanoma liver life sciences
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
Published: 2023-04-18 (Crawled : 14:00) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K
|
|
| O: 4.97%
H: 5.98%
C: -6.23%
liver cancer
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Published: 2023-03-10 (Crawled : 14:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -1.71%
H: 0.27%
C: -12.44%
treatment fda fibrosis liver meeting nash
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
GALT | $3.37 -0.3% -0.3% 200K
|
Health Technology
|
| O: 0.0%
H: 10.24%
C: 8.29%
cirrhosis liver therapeutics study
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
CMMB | News | $0.691 -1.29% -1.3% 15K
|
Manufacturing
|
| O: 50.31%
H: 11.23%
C: -38.88%
cm-101 fibrosis liver biomarker trial results nash phase 2b
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Published: 2022-12-05 (Crawled : 14:00) - globenewswire.com
HEPA | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.13%
H: 6.63%
C: -0.88%
pharmaceuticals liver trial phase 2
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 2.1%
H: 0.56%
C: 0.56%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 1.54%
H: 4.55%
C: 3.79%
treatment rare liver
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
Published: 2022-06-23 (Crawled : 14:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
liver presentation disease
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
liver disease international
Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 14:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 5.07%
H: 5.29%
C: -3.89%
liver international
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
ALBO | $44.15 -0.23% 0.39% 1.2M
|
Health Technology
|
| O: 1.3%
H: 0.4%
C: -4.64%
liver disease week
Collagen Market to Advance at CAGR of 5.5% during Forecast Period; Substantial Demand in Drug Delivery Systems Propelling Revenue Gains, Finds TMR Study
Published: 2022-03-21 (Crawled : 14:00) - prnewswire.com
IART | News | $28.68 -9.33% -10.29% 2.9M
|
Health Technology
|
| O: 0.01%
H: 1.41%
C: 0.86%
ema drug liver propel system drug delivery
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.